Component

Erinacine-S-containing Hericium mycelial extract

Species, preparation, dose and limitations are retained on linked claims.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. In rats, oral mycelial extract equivalent to 50 mg/kg erinacine S gave 15.13% estimated absolute bioavailability and distributed erinacine S to brain and multiple peripheral organs.

    Experimental context and source evidence
    dose
    Oral extract equivalent to 50 mg/kg erinacine S; IV 5 mg/kg
    duration
    24-hour excretion and tissue sampling
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Sprague-Dawley rats
    limitations
    This is rat exposure from an extract; it does not establish a human neurological dose.
    nutrient_topic
    Hericenones & Erinacines chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Hericenones and erinacines
    organism
    Sprague-Dawley rats
    plain_language
    In rats, oral mycelial extract equivalent to 50 mg/kg erinacine S gave 15.13% estimated absolute bioavailability and distributed erinacine S to brain and multiple peripheral organs.
    primary_references
    Absolute Bioavailability, Tissue Distribution, and Excretion of Erinacine S in Hericium erinaceus Mycelia. (2019). https://pubmed.ncbi.nlm.nih.gov/31022946/ DOI: 10.3390/molecules24081624
    route
    Oral and intravenous
    tissue
    LC-MS/MS bioavailability, distribution and excretion

    Hericenones & Erinacines: mechanism of action and interactions (2026-09-20) · lines 121–130

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Sprague-Dawley rats · source_derived_draft · unverified_draft

    ## hericenones-erinacines-erinacine-s-rat-pk In rats, oral mycelial extract equivalent to 50 mg/kg erinacine S gave 15.13% estimated absolute bioavailability and distributed erinacine S to brain and multiple peripheral organs. Model/species: Sprague-Dawley rats Tissue/system: LC-MS/MS bioavailability, distribution and excretion Exposure: Oral extract equivalent to 50 mg/kg erinacine S; IV 5 mg/kg Route: Oral and intravenous Duration: 24-hour excretion and tissue sampling Limits: This is rat exposure from an extract; it does not establish a human neurological dose. Primary reference: Absolute Bioavailability, Tissue Distribution, and Excretion of Erinacine S in Hericium erinaceus Mycelia. (2019). https://pubmed.ncbi.nlm.nih.gov/31022946/ DOI: 10.3390/molecules24081624 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards